Divalproex sodium in headache: Literature review and clinical guidelines

Headache

Volumn 36, Issue 9, 1996, Pages 547-555

  Silberstein, Stephen D ^a  

^a Germantown Hosp and Medical Center   (United States)

Author keywords

divalproex sodium; migraine; placebo controlled studies; preventive migraine treatment; valproic acid

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ERGOTAMINE; PROPRANOLOL; VALPROATE SEMISODIUM; VALPROIC ACID; VALPROMIDE;

ANTICONVULSANT ACTIVITY; ARTICLE; ASTHENIA; CLINICAL STUDY; CLINICAL TRIAL; CLUSTER HEADACHE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG INDICATION; ENTERIC COATED TABLET; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MIGRAINE; MULTICENTER STUDY; PHARMACEUTICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VERTIGO;

CHRONIC DISEASE; CLINICAL TRIALS; DOUBLE-BLIND METHOD; HEADACHE; HUMANS; MIGRAINE DISORDERS; RISK FACTORS; VALPROIC ACID;

EID: 0029861594     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.1996.3609547.x     Document Type: Article

References (66)

1. Physicians' Desk Reference. 49th ed. New Jersey: Medical Economics Company; 1995.
2. Bourgeois FD. Valproic acid. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. 4th ed. New York: Raven Press; 1995:633-639.
3. Balfour JA, Bryson HM. Valproic acid. A review of its pharmacology and therapeutic potential in indications other than epilepsy. CNS Drugs. 1994;2:144-173.
4. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a tripleblind, placebo-controlled crossover study. Neurology. 1994;44:647-651.
5. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52:281-286.
6. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia. 1992;12:81-84.
7. Klapper J. Divalproex sodium in the prophylactic treatment of migraine. Headache. 1995;35:290. Abstract.
8. Roy-Byrne PP, Ward NG, Donnelly PJ. Valproate in anxiety and withdrawal syndromes. J Clin Psychiatry. 1989;50:44-48.
9. Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache. An open label study. Headache. 1991;31:71-74.
10. Hering R, Kuritzky A. Sodium valproate in the treatment of cluster headache: an open clinical trial. Cephalalgia. 1989;9:195-198.
11. McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI. Valproate in psychiatric disorders: literature review and clinical guidelines. J Clin Psychiatry. 1989;50:23-29.
12. Rimmer EM, Richens A. An update on sodium valproate. Pharmacotherapy. 1985;5:171-184.
13. Penry JK, Dean JC. The scope and use of valproate in epilepsy. J Clin Psychiatry. 1989;50:17-22.
14. Rall TW, Schleifer LS. Drugs effective in the therapy of epilepsies (Chapter 19). In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's The Pharmacologic Basis of Therapeutics. 8th ed. New York: Pergamon Press; 1990:436-462.
15. Chapman A, Keane PE, Meldrum BS, Simiand J, Vernieres JC. Mechanism of anticonvulsant action of valproate. Prog Neurobiol. 1982;19:315-359.
16. Lloyd KG, Morselli PL. Psychopharmacology of GABAergic drugs. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 1987:183-195.
17. A receptors located outside the blood brain barrier mediate sodium valproate blockade of neurogenic and substance P-induced inflammation: possible mechanism in migraine. Proceedings of the 7th International Headache Congress; September 16-20, 1995; Toronto, Canada. Cephalalgia. 1995;15 (suppl 14):102.
18. Sorensen KV. Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand. 1988;78:346-348.
19. Viswanathan KN, Sundraram N, Rajendiran C, Manohar DS, Balaraman VT. Sodium valproate in therapy of intractable headaches with EEG changes. Cephalalgia. 1995;11:282-283.
20. Moore KL. Valproate in the treatment of refractory recurrent headaches: a retrospective analysis of 207 patients. Headache Quarterly. 1992;3:323-325.
21. Sianard-Gainko J, Lenaerts M, Bastings E, Schoenen J. Sodium valproate in severe migraine and tension-type headache: clinical efficacy and correlations with blood levels. Cephalalgia. 1993;13:252.
22. Coria F, Sempere AP, Duarte J, et al. Low-dose sodium valproate in the prophylaxis of migraine. Clin Neuropharmacol. 1994;17:569-573.
23. Rothrock JF, Kelly NM, Brody ML, Golbeck A. A differential response to treatment with divalproex sodium in patients with intractable headache. Cephalalgia. 1994;14:241-244.
24. Czapinski P. Valproic acid in preventive treatment of migraine. Cephalalgia. 1995;15(14):283.
25. Klapper J. Divalproex sodium for migraine prophylaxis. Cephalalgia. In press.
26. Kaniecki RG. A comparison of divalproex sodium to propranolol hydrochloride and placebo in the prophylaxis of migraine without aura. Investigator. 1995:1(2).
27. Klapper JA. An open label crossover comparison of divalproex sodium to propranolol HCI in the prevention of migraine headaches. Investigator. 1995;1(2).
28. Deaton RL, Thomas JR. The efficacy of divalproex sodium prophylactic treatment in patients experiencing migraine with or without aura. Proceedings of the 7th International Headache Congress; September 16-20, 1995; Toronto, Canada. Cephalalgia. 1995;15(suppl 14):268.
29. Thomas JR. The long-term safety of divalproex sodium prophylactic treatment of patients with migraine. Proceedings of the 7th International Headache Congress; September 16-20, 1995; Toronto, Canada. Cephalalgia. 1995;15(suppl 14):266.
30. Pellock JM, Pippenger CE. Adverse effects of antiepileptic drugs. In: Dodson EW, Pellock JM, eds. Pediatric Epilepsy Diagnosis and Therapy. New York: Demos Publications. In press.
31. Silberstein SD, Wilmore W. Divalproex sodium: migraine treatment and monitoring. Headache. 1996;36:239-242.
32. Beghi E, DiMascio R, Sasanelli F, et al for the Collaborative Group for Epidemiology of Epilepsy. Adverse reactions to antiepileptic drugs: a multicenter survey of clinical practice. Epilepsia. 1986;27:323-330.
33. Vencovsky E, Soucek K, Zatecka I. Comparison of the side effects of lithium and dipropylacetamide (Depamide) [in Czech]. Cesk Psychiatr. 1983;79:223-227.
34. Jeavons PM. Sodium valproate and neural tube defects. Lancet. 1982;2:1282-1283.
35. Valproate: a new cause of birth defects - report from Italy and follow-up from France. MMWR Morb Mortal Wkly Rep. 1983;32:438-439.
36. Volzke E, Doose H. Dipropylacetate (Depakine, Ergenyl) in the treatment of epilepsy. Epilepsia. 1973;14:185-193.
37. Laljee H, Parsonnage MJ. Unwanted effects of sodium valproate in the treatment of adult patients with epilepsy. In: Parsonnage M, Caldwell AD, eds. The Place of Sodium Valproate in the Treatment of Epilepsy. London: Royal Society of Medicine and Academic Press; 1980:143-158.
38. Jeavons PM. Valproic acid toxicity. In: Woodbury DM, Penry JK, Pippenger CE, eds. Antiepileptic Drugs. New York: Raven Press; 1982:601-610.
39. Dreifuss FE, Langer DH. Side effects of valproate. Am J Med. 1988;84:34-41.
40. Jeavons PM, Clark JE, Harding GF. Valproate and curly hair. Lancet. 1977;1:359.
41. Vining EPG. Cognitive dysfunction associated with antiepileptic drug therapy. Epilepsia. 1987;28(suppl 2):S18-S22.
42. Tift JP. Valproic acid. N Engl J Med. 1980;303:394-395.
43. Pedersen B, Juul-Jensen P. Electroencephalographic alterations during intoxication with sodium valproate: a case report. Epilepsia. 1984;25:121-124.
44. Mortensen PB, Hansen HE, Pedersen B, Hartmann-Andersen F, Husted SE. Acute valproate intoxication: biochemical investigations and hemodialysis treatment. Int J Clin Pharmacol Ther Toxicol. 1983;21:64-68.
45. Steiman GS, Woerpel RW, Sherard ES Jr. Treatment of accidental sodium valproate overdose with an opiate antagonist (letter). Ann Neurol. 1979;6:274.
46. Wilder BJ, Karas BJ, Penry JK, Asconape J. Gastrointestinal tolerance of divalproex sodium. Neurology. 1983;33:808-811.
47. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology. 1987;37:379-385.
48. Dreifuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities II. US experience since 1984. Neurology. 1989;39:201-207.
49. Willmore LJ, Triggs WJ, Pellock JM. Valproate toxicity: risk-screening strategies. Child Neurol. 1991;6:3-6.
50. Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities. III. US experience since 1986. Neurology. 1996;46:465-469.
51. DeVries SI. Hematologic aspects during treatment with anticonvulsant drugs. Epilepsia. 1965;6:1-15.
52. Krogh CM. Compendium of Pharmaceuticals and Specialties. 25th ed. Canada: Canadian Pharmaceutical Association; 1990.
53. Pellock JM, Willmore LJ. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology. 1991;41:961-964.
54. Gerber N, Dickinson RG, Harland RC, et al. Reye-like syndrome associated with valproic acid therapy. J Pediatr. 1979;95:142-144.
55. van Egmond H, Degomme P, de Simpel H, Dierick AM, Roels H. A suspected case of late onset sodiumvalproate-induced hepatic failure. Neuropediatrics. 1987;18:96-98.
56. Kuhara T, Inoue Y, Matsumoto M, et al. Markedly increased omega-oxidation of valproate in fulminant hepatic failure. Epilepsia. 1990;31:214-217.
57. Jellinger K, Seitelberger F. Spongy encephalopathies in infancy: spongy degeneration of CNS and progressive infantile poliodystrophy. In: Goldensohn ES, Appel SA, eds. Scientific Approaches to Clinical Neurology. Philadelphia: Lea & Febiger; 1977:363.
58. Prick M, Gabreels F, Trijbels J, et al. Progressive infantile poliodystrophy (Alper's disease) with a defect in cytochrome aa3 in muscle: a report of two unrelated patients. Clin Neurol Neurosurg. 1972;85-67.
59. Prick M, Gabreels F, Renier W, et al. Pyruvate dehydrogenase deficiency restricted to brain. Neurology. 1981;31:398-404.
60. Zimmerman HJ, Ishak KG. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology. 1982;2:591-597.
61. Berkovic SF, Bladin PF, Jones DB, Smallwood RA, Vajda FJ. Hepatotoxicity of sodium valproate. Clin Exp Neurol. 1983;19:192-197.
62. Rettie AE, Rettenmeier AW, Howald WN, Baillie TA. Cytochrome P-450 catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. Science. 1987;235:890-893.
63. Turnbull DM. Adverse effects of valproate. Adverse Drug React Ac Pois Rev. 1983;191-216.
64. Friedman JM, Polifka JE. Teratogenic Effects of Drugs: A Resource for Clinicians. Baltimore: Johns Hopkins University Press; 1994.
65. Dansky LV, Rosenblatt DS, Andermann E. Mechanisms of teratogenesis: folic acid and antiepileptic therapy. Neurology. 1992;42(suppl 5):32-42.
66. Karas BJ, Wilder BJ, Hammond EJ, Bauman AW. Treatment of valproate tremors. Neurology. 1983;33:1380-1382.